In a concise communication published in the August 2012 issue of Infection Control and Hospital Epidemiology, Erica S. Shenoy, MD, PhD, Rochelle P. Walensky, MD, MPH, Hang Lee, PhD, Benjamin Orcutt, CHAM, and David C. Hooper, MD, report on the impact of contact precautions (CP) for methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE) on time to bed assignment.Â
The researchers surveyed patient access managers (PAMs) on the impact of CP for MRSA and VRE on time to bed assignment as well as investigated the factors influencing infection control policies allowing for discontinuation of CP. The majority of respondents reported an increase in time to bed assignment for patients with a history of MRSA and/or VRE infection or colonization.
The researchers note, "This survey is the first, to our knowledge, to document the impact of CP status on bed assignment from the perspective of PAMs. We found that the vast majority (>90 percent) of responding PAMs reported spending substantially more time assigning inpatient beds to patients who required CP accommodations for MRSA/VRE, with estimates of a doubling of the time required for other patients. This difference represents a 'hidden' cost of CP that, to our knowledge, has not been previously reported. The additional time may result in lengthier emergency department stays; studies have found significant and positive associations between delays to admission for emergency department patients and patient mortality. Moreover, patient satisfaction is adversely affected by increased waiting times."
The researchers add that "Reported policies for CP discontinuation for MRSA appear to correlate with cohorting policies. It may be that capacity constraints are driving institutions both to allow cohorting and to develop internal policies for discontinuation of CP. This linkage may relate to limitations in bed availability from cohorting. For example, in circumstances in which a patient on CP occupies a semiprivate room, the second bed may go unfilled because there is no sex-identical patient requiring similar CP."
Shenoy, et al. (2012) conclude that, "Policies that do not permit removal of CP are likely unsustainable, especially considering that MRSA colonization is transient in a substantial proportion of patients. Studies to define optimal policies for CP discontinuation are needed."
Reference: Shenoy, ES, et al. Resource Burden Associated with Contact Precautions for Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus: The Patient Access Managers Perspective. Infection Control and Hospital Epidemiology. Vol. 33, No. 8. August 2012.
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.